NC-KBI-BIOPHARM/ARGONAUT
16.1.2024 13:58:26 CET | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barnes Aerospace Acquires ATL Turbine Services, Establishing First Aeroengine Component Repair Operation in Europe1.10.2026 20:50:00 CEST | Press release
ATL Turbine Services strengthens Barnes Aerospace's global repair network with specialized turbine component repair capabilities that will serve as a platform for growth across the region. Barnes Aerospace, a global provider of component engineering, manufacturing and repair solutions for the aerospace industry, today announced the acquisition of ATL Turbine Services Ltd. ("ATL Turbine Services"), a Dundee, Scotland-based specialist in the refurbishment and repair of hot-section gas turbine components, marking Barnes Aerospace's first dedicated component repair and overhaul presence in Europe. The acquisition establishes Barnes Aerospace's initial Component Repair and Overhaul (CRO) footprint in Europe, expanding the company's aftermarket presence and strengthening its ability to serve customers in the region. ATL Turbine Services brings established in-region repair, assessment, coating, and engineering capabilities that complement Barnes Aerospace's existing global repair network and
Netmore Named Smart Company of the Year at the Premios iAgua 20261.10.2026 19:00:00 CEST | Press release
Netmore recognized for commitment to Spanish water market backed by locally developed products, proven smart metering expertise, and deep local market knowledge Netmore Group, the leading network operator and platform provider for Massive IoT, today announced it has been named Empresa Smart del Año — Smart Company of the Year — at the Premios iAgua 2026, the awards of iAgua, the Spanish-speaking water sector's leading media platform. The award was presented at the closing gala of the Spain Smart Water Summit, held at the Meliá Avenida América in Madrid. The award recognises a company that has taken an unusual route into water. Netmore is not a technology firm that added connectivity to its portfolio: it is a network operator that decided to specialise in the water cycle. In eighteen months, it has completed four acquisitions and become the world's largest LoRaWAN® network operator, with more than eighteen million IoT devices under contract across more than fifty countries. Its commitme
Elliptic Sets the Engineering Bar for On-Chain Risk With “Built for Compliance” Paper as New Rules Take Hold and Banks Launch a Joint Stablecoin1.10.2026 15:40:00 CEST | Press release
Built for compliance arrives as crypto compliance rules tighten worldwide and a bank-led stablecoin enters the market Elliptic, the global leader in on-chain risk management, today published Built for compliance, a paper setting out the nine engineering decisions that determine whether an on-chain risk system can support fast, accurate and defensible compliance decisions at agentic scale. Machines are already moving money on their own, at machine speed. Compliance teams now have to make hundreds of thousands of decisions a day, at that same speed. However, many on-chain risk systems were never engineered to support that pace. A compliance system that computes exposure on a schedule delivers stale results. One that defines blockchain coverage loosely enough lets a screening miss exposure entirely. A system that skips testing disaster recovery, a spike or an outage, takes down the customer’s compliance system too. That gap between machine speed and system design is exactly what regulator
Impartner Releases AI Ecosystem Playbook to Help Organizations Move from AI Experimentation to Execution1.10.2026 15:00:00 CEST | Press release
The AI Ecosystem Playbook provides a practical framework for assessing AI readiness, identifying high-value opportunities, addressing foundational gaps, and building a roadmap for AI adoption. Impartner, the world’s leading partner revenue orchestration platform, today announced the release of its AI Ecosystem Playbook, a new resource designed to help leaders and teams assess their current AI capabilities, identify areas where AI can support business goals, and develop a practical path to implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001661549/en/ Impartner’s AI Ecosystem Playbook helps organizations assess AI readiness and identify opportunities to apply AI across PRM 3.0, partner revenue orchestration, and the partner lifecycle. As AI moves from experimentation into everyday operations, companies need more than a collection of potential applications. They need a framework for understanding where they ar
Whiteford Adds Six Partners in New York City, Expanding its Litigation, International and Corporate Practices1.10.2026 15:00:00 CEST | Press release
Lateral group joins growing Midtown Manhattan office as firm pursues targeted expansion strategy Whiteford, Taylor & Preston, a full-service law firm with offices across the East Coast, today announced that six partners from Chambers-rated Lazare Potter Glazer & Moyle LLP have joined Whiteford’s New York office: David E. Potter, James F. Moyle, Johannes K. Gäbel, Jaipat Singh Jain, Anna Pia D. Felix and Jacob Englander. This team expands Whiteford's New York office to more than two dozen attorneys and deepens the firm's commercial and securities litigation, employment, cross-border and corporate capabilities in the New York market. The six partners bring decades of combined experience representing mid-market companies, investment advisers, hedge funds, foreign corporations, entrepreneurs and executives in litigation, regulatory investigations, and complex business transactions. "We are expanding with our clients, our markets and our reputation," said Martin Fletcher, Whiteford's Managi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom